IFNG and neoplasm: In other cases, despite expression of PD-1 and PD-L1, failure of immune checkpoint inhibitors can be explained by somatic JAK1/2 mutations rendering tumor cells insensitive to IFNγ (this can be either a primary or acquired resistance mechanism) or loss of β2-microglobulin impairing tumoral antigen presentation [125,126].